Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

Medicine Matters oncology

Cobomarsen is a miR-155 inhibitor that has recently emerged as a novel candidate for systemic CTCL therapy. It has been found that STAT5 drives expression of oncogenic BIC/miR-155 in cancer, and the STAT5/BIC/miR-155 pathway has been shown to promote proliferation of malignant T cells [24]. Therefore, inhibition of miR-155 is thought to be a good target for CTCL treatment. A phase I study of MRG-106 is currently underway and preliminary results showed that 26 out of 29 evaluable subjects had improvement in mSWAT scores, suggesting that MRG-106 is well tolerated, has clinical activity, and may improve quality of life in MF [25].